Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
9.26
-0.24 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
9.15
-0.11 (-1.19%)
After-hours: Apr 28, 2026, 7:52 PM EDT
Climb Bio Employees
As of December 31, 2025, Climb Bio had 29 total employees, including 28 full-time and 1 part-time employees. The number of employees increased by 11 or 61.11% compared to the previous year.
Employees
29
Change (1Y)
11
Growth (1Y)
61.11%
Revenue / Employee
n/a
Profits / Employee
-$2,063,828
Market Cap
442.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29 | 11 | 61.11% |
| Dec 31, 2024 | 18 | 7 | 63.64% |
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| Entrada Therapeutics | 152 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Assembly Biosciences | 73 |
| Larimar Therapeutics | 71 |
CLYM News
- 15 hours ago - Climb Bio, Inc. Announces $110.0 Million Private Placement - GlobeNewsWire
- 20 days ago - Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - GlobeNewsWire
- 21 days ago - Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 7 weeks ago - Climb Bio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Climb Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Climb Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Climb Bio to Present at Upcoming Investor Conferences - GlobeNewsWire